637 related articles for article (PubMed ID: 30669516)
1. Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells.
Namekawa T; Ikeda K; Horie-Inoue K; Inoue S
Cells; 2019 Jan; 8(1):. PubMed ID: 30669516
[TBL] [Abstract][Full Text] [Related]
2. Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.
Philp LK
Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
[TBL] [Abstract][Full Text] [Related]
3. A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.
Fong EL; Wan X; Yang J; Morgado M; Mikos AG; Harrington DA; Navone NM; Farach-Carson MC
Biomaterials; 2016 Jan; 77():164-72. PubMed ID: 26599623
[TBL] [Abstract][Full Text] [Related]
4. Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.
Valta MP; Zhao H; Saar M; Tuomela J; Nolley R; Linxweiler J; Sandholm J; Lehtimäki J; Härkönen P; Coleman I; Nelson PS; Corey E; Peehl DM
Clin Exp Metastasis; 2016 Apr; 33(4):325-37. PubMed ID: 26873136
[TBL] [Abstract][Full Text] [Related]
5. A synopsis of prostate organoid methodologies, applications, and limitations.
Gleave AM; Ci X; Lin D; Wang Y
Prostate; 2020 May; 80(6):518-526. PubMed ID: 32084293
[TBL] [Abstract][Full Text] [Related]
6. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
Palanisamy N; Yang J; Shepherd PDA; Li-Ning-Tapia EM; Labanca E; Manyam GC; Ravoori MK; Kundra V; Araujo JC; Efstathiou E; Pisters LL; Wan X; Wang X; Vazquez ES; Aparicio AM; Carskadon SL; Tomlins SA; Kunju LP; Chinnaiyan AM; Broom BM; Logothetis CJ; Troncoso P; Navone NM
Clin Cancer Res; 2020 Sep; 26(18):4933-4946. PubMed ID: 32576626
[TBL] [Abstract][Full Text] [Related]
7. Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
Bigot L; Sabio J; Poiraudeau L; Annereau M; Menssouri N; Helissey C; Déas O; Aglave M; Ibrahim T; Pobel C; Nobre C; Nicotra C; Ngo-Camus M; Lacroix L; Rouleau E; Tselikas L; Judde JG; Chauchereau A; Bernard-Tessier A; Patrikidou A; Naoun N; Flippot R; Colomba E; Fuerea A; Albiges L; Lavaud P; Massard C; Friboulet L; Fizazi K; Besse B; Scoazec JY; Loriot Y
Eur Urol Oncol; 2024 Jun; 7(3):527-536. PubMed ID: 38433714
[TBL] [Abstract][Full Text] [Related]
8. Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts.
Kuwata T; Yanagihara K; Iino Y; Komatsu T; Ochiai A; Sekine S; Taniguchi H; Katai H; Kinoshita T; Ohtsu A
Cells; 2019 Jun; 8(6):. PubMed ID: 31207870
[TBL] [Abstract][Full Text] [Related]
9. Introduction of Androgen Receptor Targeting shRNA Inhibits Tumor Growth in Patient-Derived Prostate Cancer Xenografts.
Thomas PB; Alinezhad S; Joshi A; Sweeney K; Tse BWC; Tevz G; McPherson S; Nelson CC; Williams ED; Vela I
Curr Oncol; 2023 Oct; 30(11):9437-9447. PubMed ID: 37999103
[TBL] [Abstract][Full Text] [Related]
10. [Progress in prostate cancer study: 3D cell culture enables the ex vivo reproduction of tumor characteristics].
Tostivint V; Racaud-Sultan C; Roumiguié M; Soulié M; Gamé X; Beauval JB
Presse Med; 2017 Oct; 46(10):954-965. PubMed ID: 28967525
[TBL] [Abstract][Full Text] [Related]
11. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
[TBL] [Abstract][Full Text] [Related]
12. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
Pamarthy S; Sabaawy HE
Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived xenografts: A platform for accelerating translational research in prostate cancer.
Davies AH; Wang Y; Zoubeidi A
Mol Cell Endocrinol; 2018 Feb; 462(Pt A):17-24. PubMed ID: 28315377
[TBL] [Abstract][Full Text] [Related]
14. Establishment and serial passage of cell cultures derived from LuCaP xenografts.
Young SR; Saar M; Santos J; Nguyen HM; Vessella RL; Peehl DM
Prostate; 2013 Sep; 73(12):1251-62. PubMed ID: 23740600
[TBL] [Abstract][Full Text] [Related]
15. High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a Patient-derived Colon Tumor.
Okazawa Y; Mizukoshi K; Koyama Y; Okubo S; Komiyama H; Kojima Y; Goto M; Habu S; Hino O; Sakamoto K; Orimo A
J Vis Exp; 2018 Jun; (136):. PubMed ID: 29985333
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived xenografts and organoids model therapy response in prostate cancer.
Karkampouna S; La Manna F; Benjak A; Kiener M; De Menna M; Zoni E; Grosjean J; Klima I; Garofoli A; Bolis M; Vallerga A; Theurillat JP; De Filippo MR; Genitsch V; Keller D; Booij TH; Stirnimann CU; Eng K; Sboner A; Ng CKY; Piscuoglio S; Gray PC; Spahn M; Rubin MA; Thalmann GN; Kruithof-de Julio M
Nat Commun; 2021 Feb; 12(1):1117. PubMed ID: 33602919
[TBL] [Abstract][Full Text] [Related]
17. Applications of patient-derived tumor xenograft models and tumor organoids.
Yoshida GJ
J Hematol Oncol; 2020 Jan; 13(1):4. PubMed ID: 31910904
[TBL] [Abstract][Full Text] [Related]
18. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
Zhao Z; He J; Kang R; Zhao S; Liu L; Li F
Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Wahba B; Anbalagan M; Rowan B; Abazeed ME; Bunnell BA; Moroz K; Miele L; Rhodes LV; Jones SD; Martin EC; Collins-Burow BM; Burow ME
BMC Cancer; 2019 Mar; 19(1):205. PubMed ID: 30845999
[TBL] [Abstract][Full Text] [Related]
20. Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening.
Fong EL; Martinez M; Yang J; Mikos AG; Navone NM; Harrington DA; Farach-Carson MC
Mol Pharm; 2014 Jul; 11(7):2040-50. PubMed ID: 24779589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]